STOCK TITAN

Passage Bio Inc - PASG STOCK NEWS

Welcome to our dedicated news page for Passage Bio (Ticker: PASG), a resource for investors and traders seeking the latest updates and insights on Passage Bio.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Passage Bio's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Passage Bio's position in the market.

Rhea-AI Summary
Passage Bio, Inc. (NASDAQ: PASG) will present at Chardan’s 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit. The event features William Chou, M.D., president, and CEO, and Eden Fucci, SVP of technical operations, in a virtual fireside chat on April 29, 2024. Investors can watch the webcast on Passage Bio's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.87%
Tags
conferences
-
Rhea-AI Summary
Passage Bio, Inc. (PASG) announces the opening of its third annual Tachi Yamada Scholarship program, offering a $10,000 scholarship to a junior life science major at a Pennsylvania-based four-year college. The scholarship is in honor of Tachi Yamada, a co-founder of Passage Bio, and aims to support students pursuing careers in the life sciences industry. Interested sophomore students have until April 26, 2024, to apply for the scholarship.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.75%
Tags
none
-
Rhea-AI Summary
Passage Bio, Inc. (PASG) reports positive financial results and progress in the upliFT-D trial of PBFT02 for frontotemporal dementia (FTD) treatment. The company expands clinical trial sites into Europe and activates seven global sites. PBFT02 shows potential in treating various neurodegenerative diseases, with a strong balance sheet until Q4 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.18%
Tags
Rhea-AI Summary
Passage Bio, Inc. (PASG) will participate in investor conferences like TD Cowen 44th Annual Health Care Conference and Leerink Partners Global Biopharma Conference to discuss their clinical-stage genetic medicines for neurodegenerative diseases. A webcast will be available for investors on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.12%
Tags
conferences
-
Rhea-AI Summary
Passage Bio, Inc. (PASG) announced that its CEO will participate in a fireside chat at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference. The event will be live webcasted and available for replay on the company's website. The focus of the company is on genetic medicines for neurodegenerative diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.08%
Tags
conferences
-
Rhea-AI Summary
Passage Bio, Inc. (Nasdaq: PASG) announced initial safety and biomarker data from three Cohort 1 patients in the ongoing global Phase 1/2 upliFT-D clinical trial evaluating PBFT02, an adeno-associated virus (AAV)-delivery gene therapy for the treatment of patients with frontotemporal dementia (FTD) with granulin (GRN) mutations. The data showcased PBFT02's ability to elevate CSF progranulin to supraphysiologic levels at the lowest tested dose, Dose 1, up to six months post-treatment. The company also shared strategic priorities aimed at further optimizing its portfolio for the treatment of neurodegenerative conditions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.38%
Tags
Rhea-AI Summary
Passage Bio, Inc. (Nasdaq: PASG) grants 10,400 shares of common stock as an inducement award to a new employee, in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $0.628 per share, equal to the closing price on November 15, 2023. The shares will vest over four years, with 25% vesting after one year, and the remainder in 36 equal monthly installments, subject to continued employment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Passage Bio, Inc. (PASG) reports progress in clinical trials for FTD and GM1 treatment, with a strong financial position and extended cash runway. The company expects to present initial safety and biomarker data from three Cohort 1 patients in the upliFT-D trial for FTD in Q4 2023 and from Dose 3 patients in the Imagine-1 trial for GM1 in mid-2024. With a robust balance sheet, Passage Bio is well-positioned to achieve meaningful clinical milestones.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Passage Bio, Inc. (NASDAQ: PASG) announced that its CEO, William Chou, will participate in a fireside chat at Guggenheim’s 5th Annual Inflammation, Neurology & Immunology Conference on November 6, 2023 at 2:30 p.m. ET. The event will be webcasted live on Passage Bio's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.93%
Tags
conferences
Rhea-AI Summary
Passage Bio grants inducement awards to new employees
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.09%
Tags
none
Passage Bio Inc

Nasdaq:PASG

PASG Rankings

PASG Stock Data

82.56M
37.41M
0.32%
55.75%
2.38%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States
Philadelphia

About PASG

passage bio, inc., a genetic medicines company, develops transformative therapies for rare monogenic central nervous system (cns) diseases. the company develops pbgm01, which utilizes a proprietary, aavhu68 capsid to deliver to the brain and peripheral tissues a functional glb1 gene encoding lysosomal acid beta-galactosidase (ãŸ-gal) for infantile gm1; pbft02, which utilizes an aav1 capsid to deliver to the brain a functional granulin, or grn, gene encoding progranulin for the treatment of ftd caused by a deficiency of progranulin; and pbkr03, which utilizes a proprietary, aavhu68 capsid to deliver to the brain and peripheral tissues a functional galc gene encoding the hydrolytic enzyme galactosylceramidase, for infantile krabbe disease. it has a strategic research collaboration with the trustees of the university of pennsylvania's gene therapy program; and collaboration agreement, and a development services and clinical supply agreement with catalent maryland, inc. the company was fou